Change in the nomination committee's proposal regarding board members
The nomination committee of Swedish Orphan Biovitrum (Sobi) has decided to
propose Helena Saxon for election as a new member of the Board of Directors
instead of Hans Glemstedt who, following changes within Investor, has decided
not to stand for re-election.
Helena Saxon serves as Investment Manager at Investor AB. She has previously
served as CFO at PR firm Hallvarsson & Halvarsson and at Syncron International.
Helena was born in 1970 and has a M.Sc. in Business and Economics from Stockholm
School of Economics.
As announced in connection with the publication of the notice to attend the
Annual General Meeting, the nomination committee proposes the re-election of
board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson, Hans
Wigzell and the election of Hans GCP Schikan as a new board member, and that Bo
Jesper Hansen be appointed Chairman of the Board of Directors. Wenche Rolfsen
and Michael Steinmetz have declined re-election.
The nomination committee consists of Petra Hedengran, Chairman (Investor AB),
Roger Johanson (Skandia Liv), Åsa Nisell (Swedbank Robur Fonder) and Chairman of
the Board of Directors of Sobi, Bo Jesper Hansen.
The Annual General Meeting will be held at 4 p.m. on April 28, 2011 in the
Wallenberg Auditorium at the Royal Swedish Academy of Engineering Sciences
(IVA), Grev Turegatan 16, Stockholm, Sweden.
For more information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Phone:+46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a Swedish based niche specialty pharmaceutical company with an
international market presence. The company is focused on providing and
developing specialist pharmaceuticals for rare disease patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer
supportive care and inherited metabolic disorders. In 2010 Sobi had revenues of
about SEK 1.9 B and approximately 500 employees. The share (STO: SOBI) is listed
on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com.
Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 18, 2011 at 11:15 a.m. CET.